Biohaven Investor and Clinician Dinner in Philadelphia

May 7, 2019

Please join Biohaven for an informative Investor and Clinician dinner as leading experts discuss the advancement of the Biohaven NOJECTION™ CGRP antagnonist platform.

Guest Speakers:
Richard Lipton, MD
Albert Einstein College of Medicine Montefiore Headache Center

David Kudrow, MD
California Medical Clinic for Headache

Jelena Pavlovic, MD
Albert Einstein College of Medicine Montefiore Headache Center


Date:
Tuesday, May 7th, 2019
 
Time:
Registration: 6:30pm
Presentation & Dinner: 7:00pm
 

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Biohaven Pharmaceuticals, Inc [BHVN] US$2,624 MM MCap
sub­mitt­ed NDAs for Zy­dis ODT (oral­ly dis­solv­ing tablet) and tablet for­mu­la­tions of rimege­pant in 2Q19. Up­com­ing mile­s­tones: 4Q19/1Q20: (1) Ph 3 to­p­line (pre­ven­tive mi­graine) (2) Ph 2/3 to­p­line (in­tra­nasal/acute treat­ment of mi­graine) (3) Ph 2/3 to­p­line (gen. anxi­e­ty di­s­or­der) (4) Ph 2/3 in­ter­im (Alzheimer's); 1Q20: (5) Ph 2/3 to­p­line (OCD) [more in­for­ma­tion]